Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Breast09 first-line HER2-positive metastatic breast cancer study
MOH_2021-07-31_010172Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of trastuzumab deruxtecan, pertuzumab and trastuzumab in HER2-positive breast cancer (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jul 2021; status: recruiting.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on MOH_2021-07-31_010172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-31_010172.